CCP110 and Huntington disease: Finally, identification of CP110 proximity interactors during proteasome inhibition revealed an enrichment in pathways associated with protein aggregation diseases, including HD, and the proteasome (Extended Data Fig. 7g–k and Supplementary Table 2).